Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $19.00.

Several equities research analysts have issued reports on ARTV shares. HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, January 27th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC grew its position in shares of Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Artiva Biotherapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after buying an additional 37,053 shares during the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics during the fourth quarter worth $341,000. Finally, Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at $67,000.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $5.74 on Monday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $7.36. The stock has a market capitalization of $140.92 million, a price-to-earnings ratio of -2.22 and a beta of 2.12. The stock has a 50 day moving average price of $4.56 and a 200 day moving average price of $3.86.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.